"Dona" is an effective drug containing glucosamine. Used to treat osteochondrosis, osteoarthritis. Promotes the restoration of cartilage and bone tissue, improves the permeability of joint capsules. Many patients (more than 80%) note the cessation of pain after several months of use. The course of therapy is long, you must first consult a doctor.
“Dona” stimulates tissue repair (elimination of damage). The active ingredient is glucosamine. Performs the functions of an analgesic and anti-inflammatory agent. Has a complex effect on joints:
- increased permeability of the joint capsule;
- replenishment of glucosamine deficiency;
- increased proteoglycan synthesis;
- increased synthesis of hyaluronic acid, which is contained in synovial fluid;
- restoration of metabolism in articular cartilage and synovial membranes;
- stimulation of chondroitinsulfuric acid synthesis;
- improving calcium absorption by bones;
- preventing the destruction of joints and bones;
- reduction of joint pain.
The drug is almost completely (90%) absorbed from the gastrointestinal tract, which ensures a biavailability level of 25%.
The product is produced in the form of tablets weighing 750 mg each and powder (1500 mg). Sold in pharmacies, dispensed without a prescription. Should be stored at room temperature (up to 25 degrees) for a total shelf life of 3 years from the date of production.
Indications and contraindications for the use of Dona tablets
The drug is used for osteochondrosis of any parts of the spine and other joints, as well as for the treatment of osteoarthritis of peripheral joints and the spine.
In some cases, use is contraindicated:
- high sensitivity to glucosamine or auxiliary components of the drug;
- severe chronic kidney failure.
With caution, the drug is given to children under 12 years of age inclusive and to women during pregnancy and lactation. It is important to understand that no studies have been conducted on the effect of the drug, so using the medicine on your own is not recommended. You must first coordinate its appointment with your doctor.
Also, tablets are used with caution by patients with diabetes and bronchial asthma. If glucose tolerance is impaired, there are problems with the liver and kidneys, use is allowed only under medical supervision. This is especially important when long-term therapy is planned.
In some cases, side effects from the use of Dona tablets and powder are observed, for example:
- flatulence;
- bloating;
- stool disorders (diarrhea);
- headaches;
- increased drowsiness;
- nausea;
- manifestations of allergies (itching, urticaria, erythema).
Buy Dona powder for oral solution 1500 mg No. 20 in pharmacies
Trade name of the drug:
Dona®
International nonproprietary name:
glucosamine
Dosage form:
powder for the preparation of solution for oral administration.
Compound:
One sachet contains:
active substance: crystalline glucosamine sulfate 1884 mg (contains glucosamine sulfate 1500 mg and sodium chloride 384 mg); excipients: aspartame, sorbitol, carbowax 4000 (macrogol 4000), citric acid.
Description
White crystalline powder.
Pharmacotherapeutic group:
tissue repair stimulator.
Pharmacological properties
Dona has an anti-inflammatory and analgesic effect, replenishes endogenous glucosamine deficiency, stimulates the synthesis of proteoglycans and hyaluronic acid in synovial fluid; increases the permeability of the joint capsule, restores enzymatic processes in the cells of the synovial membrane and articular cartilage. Promotes fixation of sulfur during the synthesis of chondroitinsulfuric acid, facilitates normal calcium deposition in bone tissue, inhibits the development of degenerative processes in joints, restores their function, reducing joint pain.
Pharmacokinetics
Absorption in the gastrointestinal tract is 90%, bioavailability is 26%, half-life is 70 hours.
Indications for use
Primary and secondary osteoarthritis, osteochondrosis, spondyloarthrosis.
Contraindications
Individual hypersensitivity to glucosamine sulfate, aspartame and other components of the drug. Due to the aspartame content, it is contraindicated in patients with phenylketonuria.
It is not recommended to prescribe the drug during pregnancy and lactation, as well as in childhood (up to 12 years) due to the lack of scientific clinical data in this category of patients.
Carefully
Caution should be exercised in patients with allergies to seafood (shrimp, shellfish).
Directions for use and doses
Inside. The contents of one sachet are dissolved in 200 ml of water and taken orally once a day. The symptomatic effect occurs 2-3 weeks after using the drug. The duration and regimen of treatment is prescribed by the attending physician. The minimum course of therapy is 6 weeks.
Side effect
The drug is well tolerated, in some cases the following are possible: gastralgia, flatulence, diarrhea, constipation, allergic reactions - urticaria, itching.
Overdose
Cases of overdose are unknown. Treatment: gastric lavage, symptomatic therapy.
Interaction with other drugs
Compatible with non-steroidal anti-inflammatory drugs, paracetamol and glucocorticosteroids. Increases the absorption of tetracyclines, reduces the absorption of semisynthetic penicillins, chloramphenicol.
special instructions
When using the drug in patients with impaired glucose tolerance, with severe liver and kidney failure, medical supervision is necessary.
Release form
3950 mg (1500 mg of glucosamine sulfate) in sachets of three-layer material made of paper, polyethylene, thermally sealed together on four sides. The plastic film is in direct contact with the contents of the bag.
20 or 30 sachets along with instructions for use are placed in a cardboard box.
Best before date
3 years. Do not use after the expiration date indicated on the packaging.
Storage conditions
Store at a temperature not exceeding 25 ºC. Keep out of the reach of children
Vacation conditions
Available without a prescription.
"Dona": instructions for use
The drug is taken 1 tablet orally in the morning and evening, preferably during a meal, with a sufficient amount of water. In the first days the effect is unnoticeable, which is normal. The first results appear after a 2-3 week continuous course. In this case, the minimum duration of therapy is from 4 to 6 weeks; tablets are often taken for several months.
After this, a break is taken for 1.5-2 months, then the cycle is repeated. The dosage, as well as the duration of therapy and the general regimen depend on the age, condition of the patient, chronic diseases and other factors.
In the case of powder, the contents of 1 sachet must be dissolved in 1 glass of water (200-250 ml) and drunk with meals. Reception is carried out only once a day. In this case, the total duration of the course is determined by the same rules as in the case of tablets.
Instructions for use of DONA® (DONA)
Suction
After oral administration of 14C-labeled glucosamine, it is rapidly and almost completely absorbed, about 90% of the radioactive tracer is detected in the systemic circulation. The absolute bioavailability of glucosamine in humans after oral administration was 44%, including the first-pass effect. After daily oral administration of 1500 mg glucosamine sulfate to healthy volunteers under fasting conditions, Cmax in plasma at steady state averaged after 3 hours (Tmax) of about 1602 ± 426 ng/ml between 1.5–4 hours (median:
- 3 h, Tmax). At steady state, AUC was 14564±4138 ng×h/ml. It is unknown whether food intake has a significant effect on oral bioavailability. The pharmacokinetics of glucosamine are linear in the dose range of 750-1500 mg with deviation from linearity at a dose of 3000 mg due to lower bioavailability. There are no gender differences in the absorption and bioavailability of glucosamine. The pharmacokinetics of glucosamine were similar in healthy volunteers and patients with knee osteoarthritis.
Distribution
After oral absorption, glucosamine is distributed in various vascular compartments, incl. synovial fluid, with an apparent Vd 37 times higher than the total fluid volume in humans. Glucosamine does not bind to plasma proteins. Therefore, it is extremely unlikely that glucosamine is capable of drug interactions when taken together with other drugs that are highly bound to plasma proteins.
Metabolism
The metabolic profile of glucosamine has not been studied, since being an endogenous substance, it is used as a “building material” for the biosynthesis of articular components of cartilage. Glucosamine is primarily metabolized by conversion to hexosamine, independent of the cytochrome system. Crystalline glucosamine sulfate does not act as either an inhibitor or inducer of human CYP450 isoenzymes, including CYP3A4, 1A2, 2E1, 2C9 and 2D6.00, even when tested at glucosamine concentrations 300 times the peak plasma concentration observed in the patient after therapeutic doses crystalline glucosamine sulfate.
There are no clinically significant interactions between glucosamine and other drugs that could occur through inhibition and/or induction of human CYP450 isoforms.
Removal
In humans, T1/2 of glucosamine from plasma is 15 hours. After oral administration of 14C-labeled glucosamine, excretion in urine was 10±9%, in feces - 11.3±0.1% of the administered dose. The average excretion of unchanged glucosamine after oral administration in humans is approximately 1% of the administered dose, suggesting that the kidney and liver do not play a significant role in the elimination of glucosamine, its metabolites and/or its degradation products.
Pharmacokinetics in various categories of patients
Pharmacokinetic studies of glucosamine have not been conducted in patients with renal or hepatic impairment. These studies were considered inappropriate due to the insignificant contribution of the liver and kidneys in the processes of metabolism, degradation and excretion of glucosamine. Therefore, given the favorable safety profile and good tolerability of glucosamine, dosage adjustment of the drug is not required in patients with renal or hepatic impairment.
The pharmacokinetics of glucosamine have not been studied in children and adolescents.
Pharmacokinetic studies have not been conducted in elderly patients, however, clinical trials of the efficacy and safety of glucosamine included mainly elderly patients. It has been shown that there is no need for dose adjustment in this category of patients.
Overdose and drug interactions
No cases of overdose have been identified. If the dose is violated, immediate gastric lavage and treatment are indicated depending on the symptoms that arise. The drug should be used with caution in patients who are allergic to various types of seafood. If the patient is on a sodium diet, he needs to follow the dosage, since one Dona tablet contains 75 mg of pure sodium.
The product is compatible with various drugs:
- glucorticosteroids;
- non-steroidal anti-inflammatory drugs;
- paracetamol and drugs based on it.
Parallel use with antibiotics leads to an increase in the therapeutic effect of drugs of the tetracycline group and a weakening of semisynthetic penicillin, as well as chloramphenicol. It is also possible to enhance the effect of coumarin anticoagulants.
Dona powder for oral solution 1500 mg No. 20
Dona powder for oral solution 1500 mg No. 20
Trade name of the drug:
Dona®
International nonproprietary name:
glucosamine
Dosage form:
powder for the preparation of solution for oral administration.
Compound:
One sachet contains:
active substance: crystalline glucosamine sulfate 1884 mg (contains glucosamine sulfate 1500 mg and sodium chloride 384 mg); excipients: aspartame, sorbitol, carbowax 4000 (macrogol 4000), citric acid.
Description
White crystalline powder.
Pharmacotherapeutic group:
tissue repair stimulator.
Pharmacological properties
Dona has an anti-inflammatory and analgesic effect, replenishes endogenous glucosamine deficiency, stimulates the synthesis of proteoglycans and hyaluronic acid in synovial fluid; increases the permeability of the joint capsule, restores enzymatic processes in the cells of the synovial membrane and articular cartilage. Promotes fixation of sulfur during the synthesis of chondroitinsulfuric acid, facilitates normal calcium deposition in bone tissue, inhibits the development of degenerative processes in joints, restores their function, reducing joint pain.
Pharmacokinetics
Absorption in the gastrointestinal tract is 90%, bioavailability is 26%, half-life is 70 hours.
Indications for use
Primary and secondary osteoarthritis, osteochondrosis, spondyloarthrosis.
Contraindications
Individual hypersensitivity to glucosamine sulfate, aspartame and other components of the drug. Due to the aspartame content, it is contraindicated in patients with phenylketonuria.
It is not recommended to prescribe the drug during pregnancy and lactation, as well as in childhood (up to 12 years) due to the lack of scientific clinical data in this category of patients.
Carefully
Caution should be exercised in patients with allergies to seafood (shrimp, shellfish).
Directions for use and doses
Inside. The contents of one sachet are dissolved in 200 ml of water and taken orally once a day. The symptomatic effect occurs 2-3 weeks after using the drug. The duration and regimen of treatment is prescribed by the attending physician. The minimum course of therapy is 6 weeks.
Side effect
The drug is well tolerated, in some cases the following are possible: gastralgia, flatulence, diarrhea, constipation, allergic reactions - urticaria, itching.
Overdose
Cases of overdose are unknown. Treatment: gastric lavage, symptomatic therapy.
Interaction with other drugs
Compatible with non-steroidal anti-inflammatory drugs, paracetamol and glucocorticosteroids. Increases the absorption of tetracyclines, reduces the absorption of semisynthetic penicillins, chloramphenicol.
special instructions
When using the drug in patients with impaired glucose tolerance, with severe liver and kidney failure, medical supervision is necessary.
Release form
3950 mg (1500 mg of glucosamine sulfate) in sachets of three-layer material made of paper, polyethylene, thermally sealed together on four sides. The plastic film is in direct contact with the contents of the bag.
20 or 30 sachets along with instructions for use are placed in a cardboard box.
Best before date
3 years. Do not use after the expiration date indicated on the packaging.
Storage conditions
Store at a temperature not exceeding 25 ºC. Keep out of the reach of children
Vacation conditions
Available without a prescription.
Dona 1500 mg 20 pcs. powder for solution for oral administration
pharmachologic effect
Tissue repair stimulator.
Composition and release form Dona 1500 mg 20 pcs. powder for solution for oral administration
Powder - 1 pack:
- active substance: crystalline glucosamine sulfate - 1884 mg (contains glucosamine sulfate 1500 mg and sodium chloride 384 mg);
- excipients: aspartame, sorbitol, carbowax 4000 (macrogol 4000), citric acid.
3950 mg (1500 mg of glucosamine sulfate) in sachets of three-layer material made of paper, polyethylene, thermally sealed together on four sides. The plastic film is in direct contact with the contents of the bag.
20 or 30 sachets along with instructions for use are placed in a cardboard box.
Description of the dosage form
White crystalline powder.
Characteristic
Glucosamine sulfate is a natural component of articular cartilage, physiologically present in the human body. It is an aminosaccharide with low molecular weight, thoroughly purified from macromolecular components.
Directions for use and doses
Inside. The contents of one sachet are dissolved in 200 ml of water and taken orally once a day. The symptomatic effect occurs 2-3 weeks after using the drug. The duration and regimen of treatment is prescribed by the attending physician. The minimum course of therapy is 6 weeks.
Pharmacodynamics
DONA has an anti-inflammatory and analgesic effect, replenishes endogenous glucosamine deficiency, stimulates the synthesis of proteoglycans and hyaluronic acid in synovial fluid; increases the permeability of the joint capsule, restores enzymatic processes in the cells of the synovial membrane and articular cartilage. Promotes fixation of sulfur during the synthesis of chondroitinsulfuric acid, facilitates normal calcium deposition in bone tissue, inhibits the development of degenerative processes in joints, restores their function, reducing joint pain.
Pharmacokinetics
Absorption in the gastrointestinal tract is 90%, bioavailability is 26%, half-life is 70 hours.
Indications for use of Don 1500 mg 20 pcs. powder for solution for oral administration
Primary and secondary osteoarthritis, osteochondrosis, spondyloarthrosis.
Contraindications
Individual hypersensitivity to glucosamine sulfate, aspartame and other components of the drug. Due to the aspartame content, it is contraindicated in patients with phenylketonuria.
It is not recommended to prescribe the drug during pregnancy and lactation, as well as in childhood (up to 12 years) due to the lack of scientific clinical data in this category of patients.
Caution should be exercised in patients with allergies to seafood (shrimp, shellfish).
special instructions
When using the drug in patients with impaired glucose tolerance, with severe liver and kidney failure, medical supervision is necessary.
Overdose
Cases of overdose are unknown. Treatment: gastric lavage, symptomatic therapy.
Side effects of Don 1500 mg 20 pcs. powder for solution for oral administration
The drug is well tolerated, in some cases the following are possible: gastralgia, flatulence, diarrhea, constipation, allergic reactions - urticaria, itching.
Drug interactions
Compatible with non-steroidal anti-inflammatory drugs, paracetamol and glucocorticosteroids. Increases the absorption of tetracyclines, reduces the absorption of semisynthetic penicillins, chloramphenicol.
